ClinicalTrials.gg
Enrolling by invitationNCT07264231PREGFITUpdated Dec 4, 2025

Exercise During Pregnancy: Effects on the Maternal-Fetal Unit

An interventional study of Intervention in Pregnancy, sponsored by Universidad Pública de Navarra. Enrolling by invitation at 1 site in Spain. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Universidad Pública de Navarra · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.

Planned enrollment
312th of 539
64 · median 80
Started
2025
with 76 others
No phase
515 of 597
125 open now
Primary completion
2027-12
later than 160 of 183 live
Registered
509th of 597
by date

Among the 597 studies in Motor Activity with a site in Spain, this one is the 312th largest by planned enrollment of the 539 interventional ones that give a count, is one of 77 that started in 2025, is one of 515 with no phase, reaches primary completion later than 160 of the 183 other live ones, and was the 509th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 597 studies in Motor Activity with a site in Spain, or all of them as a file.
02

Study summary

Metabolic alterations during pregnancy have been associated with adverse maternal-fetal outcomes, including low birth weight and pregnancy complications. Maternal endothelial dysfunction, oxidative stress, insulin resistance, and placental mitochondrial dysfunction are thought to contribute to fetal metabolic disturbances. Lifestyle changes, such as structured exercise during pregnancy, may modulate maternal and placental factors.

This randomized controlled trial will evaluate the effects of a multicomponent exercise program during the second and third trimester on maternal functional capacity, vascular health, anthropometry, metabolic biomarkers, placental function, and newborn health outcomes.

Read the detailed description

To investigate the effects of a multicomponent supervised exercise program during pregnancy on the maternal-fetal unit.

03

Conditions studied

  • Pregnancy

Browse trials for

Keywords

  • Exercise
  • Motor Activity
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primigravid women
  • Gestational age 16-20 weeks
  • No severe malformations on ultrasound
  • Regular prenatal care and medical clearance from obstetrician
  • Being healthy and able to exercise following American College of Obstetricians and Gynecologists (ACOG) guidelines

Exclusion criteria

Exclusion Criteria:

  • Medical or obstetric complication excluding exercise ( ACOG guideline) Major surgery or trauma in past year
  • Cancer diagnosis
  • Cervical incompetence
  • History of ≥2 spontaneous abortions
  • Multiple pregnancy
  • Vaginal bleeding, placenta previa, or threatened abortion
  • , asthma, or chronic bronchitis
  • Renal, musculoskeletal, cardiovascular, or systemic infections limiting exercise
  • Polyhydramnios or oligohydramnios
  • Not availability to attend to the physical exercise program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Exercise training

    Participants will perform a supervised aerobic exercise program at 70% of maximum heart rate (HRmax), for 45 minutes per session, 3 times per week, during 12 weeks. Each session will follow a standardized protocol: 10 minutes of warm-up, 30 minutes of aerobic exercise, 5 minutes of cool-down and stretching. In addition, strength training sessions will be included 1-2 times per week. All exercise sessions will be delivered by qualified professionals, including exercise specialists, nutritionists, and physiotherapists with \>3 years of experience and a master's-level education in the field. The intervention will be conducted at the Exercise Physiology Unit (E-FIT Group Laboratory), Navarrabiomed Research Center, Pamplona, Spain.

    Behavioral: Intervention

  • No intervention
    Control

    Usual care as provided by the health services in Spain. The investigators will not advice the women to be inactive.

Interventions

  • BehavioralIntervention

    Exercise

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness (Vo2max)

    The modified cycle protocol will be performed to estimate maximal oxygen uptake (VO2max), and will be used as measure of cardiorespiratory fitness.

    Time frame: at the 16th and 34-36th week of gestation

  2. Maternal weight gain (kg)

    Maternal weight gain will be defined as the weight change from baseline measurement to the last measurement

    Time frame: 34-36th week of gestation

Secondary outcomes

  1. Systolic and diastolic blood pressure (mmHg)

    Systolic and diastolic blood pressure (mmHg) will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis.

    Time frame: at the 16th and 34-36th week of gestation

  2. Resting heart rate (bpm)

    Resting heart rate (bpm), will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis.

    Time frame: at the 16th and 34-36th week of gestation

  3. Muscle strength (kg)

    The handgrip strength and leg press test will be used as measure of strength (upper and lower limbs)

    Time frame: at the 16th and 34-36th week of gestation

  4. Whole bone mineral density (g/cm2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  5. Fat free mass

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  6. Lean mass/fat mass ratio

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  7. Fat mass (kg)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  8. Fat mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  9. Appendicular lean mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  10. Lean mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  11. Lean mass (kg)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: at the 16th to 34-36th week of gestation

  12. Physical activity and sedentary behaviour (in minutes)

    Accelerometry will be used to objectively assess physical activity and sedentary time. Women will be asked to wear a tri-axial accelerometer (ActiSleep+, Pensacola, Florida, United States) for 5-7 consecutive days, starting the same day they receive the monitor (e.g. participants who receive the accelerometer on Monday, will carry the device until Tuesday of the next week).

    Time frame: at the 16th and 34-36th week of gestation

  13. Pittsburgh Sleep Quality Index

    Accelerometry will be used to objectively assess physical activity and sedentary time. Women will be asked to wear a tri-axial accelerometer (ActiSleep+, Pensacola, Florida, United States) for 5-7 consecutive days, starting the same day they receive the monitor (e.g. participants who receive the accelerometer on Monday, will carry the device until Tuesday of the next week).

    Time frame: at the 16th and 34-36th week of gestation

  14. Quality of life (EQ-5D-5L)

    We will use the EQ-5D-5L survey, for assessing health-related quality of life, ranging from 0 ("worst imaginable health state") to 100 ("best imaginable health state"), with higher scores representing better perceived health.

    Time frame: at the 16th and 34-36th week of gestation

  15. Epidemiological Studies-Depression Scale questionnaire

    The pregnant antenatal depression levels will be assessed by the Center for Epidemiological Studies-Depression Scale questionnaire, which is validated and widely employed in pregnancy. The total score ranges from 0 to 60, with higher scores indicating more severe depressive symptoms.

    Time frame: at the 16th and 34-36th week of gestation

  16. Oswestry Disability Index score

    Low-back pain will be assessed with the Spanish version of the Oswestry Disability Index (ODI) score. The final ODI score ranges from 0 to 100, where 0 represents no disability and 100 represents maximum disability.

    Time frame: at the 16th and 34-36th week of gestation

  17. Physical Activity index

    Physical Activity will be assessed with the Spanish adaptation and validation of the Pregnancy Physical Activity Questionnaire (PPAQ). The scale ranges from 0 to 400+ MET·h/week, with higher scores indicating greater energy expenditure and physical activity levels.

    Time frame: at the 16th and 34-36th week of gestation

  18. Pain Visual Analogue Scale

    General or specific pain intensity will also be assessed using the Pain Visual Analogue Scale (VAS), a validated self-reported measure of perceived pain intensity. The VAS consists of a 10-centimeter horizontal line anchored by "no pain" (0) and "worst imaginable pain" (10) at each end. Participants will indicate their current pain level by marking a point along the line, with higher scores representing greater pain intensity.

    Time frame: at the 16th and 34-36th week of gestation

  19. Cognitive Function

    Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a validated screening tool that evaluates multiple cognitive domains, including executive function, memory, attention, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: at the 16th and 34-36th week of gestation

  20. Adherence to the Mediterranean Diet

    Adherence to the Mediterranean dietary pattern will be assessed using the Mediterranean Diet Adherence Screener (MEDAS), a validated 14-item questionnaire designed to evaluate compliance with key components of the Mediterranean diet. Each item is scored 0 or 1, depending on whether the dietary criterion is met, yielding a total score ranging from 0 to 14, where higher scores indicate greater adherence to the Mediterranean diet.

    Time frame: at the 16th and 34-36th week of gestation

  21. Psychological Distress

    The Kessler Psychological Distress Scale (K10) will be used to assess nonspecific psychological distress, including symptoms of anxiety and depression, experienced over the past four weeks. The K10 consists of 10 items, each rated on a 5-point Likert scale ranging from 1 (none of the time) to 5 (all of the time), resulting in a total score between 10 and 50. Higher scores indicate greater psychological distress.

    Time frame: at the 16th and 34-36th week of gestation

  22. Erythrocytes

    Erythrocyte count (×10⁶ cells/µL), will be measured using an automated Coulter haematology analyser (Brand, City, Country).

    Time frame: at 34th week of gestation and at delivery

  23. Lipid profile (in mother and cord blood)

    Plasma total, high-density lipoprotein and low-density lipoprotein cholesterol and triglycerides (all in mg/dL) will be assessed using an autoanalyzer.

    Time frame: at 34th week of gestation and at delivery

  24. Plasma glucose (in mother and cord blood)

    Plasma glucose concentrations will be determined using the glucose oxidase enzymatic colorimetric method.

    Time frame: at 34th week of gestation and at delivery

  25. Total plasma antioxidant capacity (in mother and cord blood)

    Total plasma antioxidant capacity (in maternal and cord blood) will be measured using a commercial colorimetric assay kit based on spectrophotometry, following the manufacturer's instructions. Results will be expressed in Trolox equivalents (mmol Trolox/L), where higher values indicate greater antioxidant capacity.

    Time frame: at 34th week of gestation and at delivery

  26. Antioxidant enzymes activity (in mother and cord blood)

    Erythrocyte membrane catalase, glutathione peroxidase, and superoxide dismutase enzyme activities will be measured by spectrophotometry using standard biochemical assays. Results will be expressed in units per milligram of hemoglobin (U/mg Hb), where higher values indicate greater enzymatic antioxidant activity.

    Time frame: at 34th week of gestation and at delivery

  27. Pro- and anti-inflammatory signal (in mother and cord blood)

    Some maternal and umbilical cord plasma pro-inflammatory and anti-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-10, IFN-γ and TNF-α, IL-1ra and TNF Srii α), some adipokines (adiponectin, adipsin, resistin, PAI-active, insulin and leptin) and myokines (irisin) will be measured by the employment of Luminex xMAP technology. Other relevant biomarkers related to bone metabolism (ACTH, DKK-1, FGF-23, Osteocalcin, OPN-Osteopontin, Osteoprotegerin, PTH and SOST) will be measured with Luminex xMAP technology. Each outcome will be reported separately, with concentrations expressed in pg/mL or ng/mL, as appropriate for the specific analyte.

    Time frame: at 34th week of gestation and at delivery

  28. Birth weight

    Birth weight will be recorded in grams (g).

    Time frame: At delivery

  29. Delivery complications

    Mode of delivery (vaginal or caesarean section) and any maternal or neonatal complications occurring during delivery will be obtained from hospital medical records and classified according to the attending obstetrician's report.

    Time frame: At delivery

  30. Apgar score

    Apgar score will be evaluated at 1 and 5 minutes after delivery by trained obstetric or neonatal staff, following standard clinical procedures. Scores range from 0 to 10, with higher values indicating better neonatal condition.

    Time frame: At delivery

  31. Polypharmacy

    Polypharmacy will be defined as the concurrent use of five or more medications.

    Time frame: At delivery and 6 and 12 months postpartum

  32. Resting energy expenditure

    Resting energy expenditure is measured in the fasting and fed state by indirect calorimetry

    Time frame: at the 16th and 34-36th week of gestation

  33. Haematocrit

    Haemoglobin concentration (g/dL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).

    Time frame: at 34th week of gestation and at delivery

  34. Platelet count and leukocyte

    Platelet count (×10³ cells/µL) and leukocyte count (×10³ cells/µL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).

    Time frame: at 34th week of gestation and at delivery

  35. Mean corpuscular volume

    Mean corpuscular volume (fL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).

    Time frame: at 34th week of gestation and at delivery

  36. Insulin levels (in mother and cord blood)

    Plasma insulin levels will be quantified by enzyme-linked immunosorbent assay (ELISA).

    Time frame: at 34th week of gestation and at delivery

  37. Glycosylated haemoglobin levels (in mother and cord blood)

    Glycosylated haemoglobin (HbA1c) will be determined using the enzymatic colorimetric method.

    Time frame: at 34th week of gestation and at delivery

  38. Body length and head circumference

    Length in centimeters (cm), and head circumference in centimeters (cm).

    Time frame: At delivery

  39. Hospitalization days

    Hospitalization will be recorded as the number and duration of inpatient stays.

    Time frame: At delivery

  40. Cost-effectiveness analyses

    Cost-effectiveness analyses will be conducted based on health service utilization and associated costs extracted from the hospital database. Each outcome will be reported separately, with appropriate units (e.g., number of admissions, days hospitalized, number of medications, EQ-5D-5L index score, euros): Count (episodes, days, or medications), EQ-5D-5L index (score), and euros (€).

    Time frame: At delivery and 6 and 12 months postpartum

Other outcomes

  1. Placental mitochondrial leak respiration

    Mitochondrial oxygen (O₂) flux will be measured in placental tissue using high-resolution respirometry (Oroboros O₂k, Oroboros Instruments, Innsbruck, Austria). Tissue samples will be analyzed in fresh homogenates under controlled substrate-uncoupler-inhibitor titration (SUIT) protocols to evaluate basal, leak, and maximal respiratory states. Oxygen flux will be expressed as picomoles of O₂ consumed per second per milligram of tissue (pmol O₂·s-¹·mg-¹).

    Time frame: At delivery

  2. Changes to maternal, placenta and umbilical cord proteome

    Changes in proteome will be analyzed using the Olink® proximity extension assay (PEA) technology, following the manufacturer's standardized protocol (Olink Proteomics, Uppsala, Sweden). Protein abundance will be expressed as normalized protein expression (NPX) units, where higher NPX values indicate greater relative protein concentration.

    Time frame: At delivery

07

Study locations

1 site
  • Navarrabiomed, Hospital Universitario de Navarra (HUN) and Universidad Pública de Navarra (UPNA)
    Pamplona, Navarre 31010, Spain
08

References and documents

Publications

  • Ramirez-Velez R, Aguilar de Plata AC, Escudero MM, Echeverry I, Ortega JG, Salazar B, Rey JJ, Hormiga C, Lopez-Jaramillo P. Influence of regular aerobic exercise on endothelium-dependent vasodilation and cardiorespiratory fitness in pregnant women. J Obstet Gynaecol Res. 2011 Nov;37(11):1601-8. doi: 10.1111/j.1447-0756.2011.01582.x. Epub 2011 Jul 6. PubMed 21733037 ↗
  • Ramirez-Velez R, Lobelo F, Aguilar-de Plata AC, Izquierdo M, Garcia-Hermoso A. Exercise during pregnancy on maternal lipids: a secondary analysis of randomized controlled trial. BMC Pregnancy Childbirth. 2017 Nov 28;17(1):396. doi: 10.1186/s12884-017-1571-6. PubMed 29179683 ↗
  • Pinzon DC, Zamora K, Martinez JH, Florez-Lopez ME, de Plata AC, Mosquera M, Ramirez-Velez R. Type of delivery and gestational age is not affected by pregnant Latin-American women engaging in vigorous exercise: a secondary analysis of data from a controlled randomized trial. Rev Salud Publica (Bogota). 2012 Oct;14(5):731-43. PubMed 24652353 ↗

Individual participant data

Plan to share: No — This section provides details of the study plan, including how the study is designed and what the study is measuring.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 27 months is above that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Dec 4, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 20, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264231
Lead sponsor
Universidad Pública de Navarra
Collaborators
Fundación Instituto de Investigación Sanitaria de Navarra, NavarraBiomed Biomedical Research Center, Complejo Hospitalario de Navarra
Responsible party
Robinson Ramírez-Vélez (Principal Investigator, Universidad Pública de Navarra) — Principal investigator
First posted
Dec 4, 2025
Start date
Sep 1, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Dec 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion